Low Financial LeverageZero reported debt is a durable strength: it lowers solvency risk and preserves financial flexibility to fund R&D, capex, or bridge cash burn without immediate default pressure. Over 2–6 months this reduces refinancing risk and gives management optionality for strategic moves.

Proprietary Production CapabilityFocus on fermentation and downstream processing is a structural business advantage: proprietary manufacturing know-how can enable scale and lower unit costs for bioplastics. As demand for sustainable materials grows, process IP and scaleability support durable competitive positioning.

Improving Equity BaseAn increasing equity base provides a more stable capital cushion to absorb losses and fund scaling efforts without immediate insolvency. Over the medium term this reduces short-term liquidity stress and can lower the need for highly dilutive emergency financings.

Bears Say

Revenue Decline And VolatilitySteep, erratic revenue trends erode the firm's ability to build scale and leverage fixed-cost production. Over 2–6 months this undermines prospects for sustainable unit economics, makes forecasting harder, and heightens the risk that operations remain loss-making despite scale efforts.

Persistent Negative Cash GenerationDeep, ongoing operating and free cash outflows indicate the business cannot fund operations internally and must rely on external capital. Persisting cash burn over months raises dilution and financing risk and constrains investment in scale or commercialization initiatives.

Deep Negative MarginsSustained negative gross and operating margins show the cost base exceeds revenue generation, preventing reinvestment and eroding shareholder equity. Unless structural cost reduction or significant revenue scale occurs, profitability metrics will continue to impair long-term viability.

Bioextrax AB News

Is 85X0 a Buy, Before Earnings?

Bioextrax AB (85X0) is scheduled to report 4th quarter earnings on 02/19/2026. Regarding Q4 estimates, Wall Street analysts...

20h ago

85X0 FAQ

What was Bioextrax AB’s price range in the past 12 months?

Bioextrax AB lowest stock price was €0.15 and its highest was €0.34 in the past 12 months.

What is Bioextrax AB’s market cap?

Bioextrax AB’s market cap is €12.41M.

When is Bioextrax AB’s upcoming earnings report date?

Bioextrax AB’s upcoming earnings report date is Feb 19, 2026 which is tomorrow.

How were Bioextrax AB’s earnings last quarter?

Bioextrax AB released its earnings results on Nov 21, 2025. The company reported €0 earnings per share for the quarter, beating the consensus estimate of -€0.01 by €0.01.

Is Bioextrax AB overvalued?

According to Wall Street analysts Bioextrax AB’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Bioextrax AB pay dividends?

Bioextrax AB does not currently pay dividends.

What is Bioextrax AB’s EPS estimate?

Bioextrax AB’s EPS estimate is 0.

How many shares outstanding does Bioextrax AB have?

Bioextrax AB has 46,306,927 shares outstanding.

What happened to Bioextrax AB’s price movement after its last earnings report?

Bioextrax AB reported an EPS of €0 in its last earnings report, beating expectations of -€0.01. Following the earnings report the stock price went up 4.07%.

Which hedge fund is a major shareholder of Bioextrax AB?

Currently, no hedge funds are holding shares in DE:85X0

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Bioextrax AB

Bioextrax AB (publ) develops and commercializes a bio-based extraction platform technology. It harvests bioplastics (PHA) granules, organic hydrolyzed protein, keratin fibers, bio-oils, protein-rich by products, and amino acids from bacteria. The company was incorporated in 2014 and is based in Lund, Sweden.